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Chromosomal rearrangements without gene fusions
have been implicated in leukemogenesis by causing
deregulation of proto-oncogenes via relocation of
cryptic regulatory DNA elements. AML with inv(3)/
t(3;3) is associated with aberrant expression of
the stem-cell regulator EVI1. Applying functional
genomics and genome-engineering, we demonstrate
that both 3q rearrangements reposition a distal
GATA2 enhancer to ectopically activate EVI1 and
simultaneously confer GATA2 functional haploin-
sufficiency, previously identified as the cause
of sporadic familial AML/MDS and MonoMac/
Emberger syndromes. Genomic excision of the
ectopic enhancer restored EVI1 silencing and led to
growth inhibition and differentiation of AML cells,
which could be replicated by pharmacologic BET in-
hibition. Our data show that structural rearrange-
ments involving the chromosomal repositioning of a
single enhancer can cause deregulation of two unre-
lated distal genes, with cancer as the outcome.
INTRODUCTION
Chromosomal inversions and translocations play a central role in
the pathogenesis of almost all types of cancers, frequently by
formation of oncogenic fusion genes via rearrangement of
coding sequences of the involved partner genes (Fro¨hling and
Do¨hner, 2008; Mitelman et al., 2004, 2013). Mechanisms of
transformation remain largely unknown in malignancies arising
from chromosomal inversions/translocations that do not causefusion products, although it is thought that destabilization of
cryptic regulatory elements affects genes in the vicinity of the
structural rearrangement, as has been shown in Burkitt’s (Polack
et al., 1993) or follicular lymphoma (Bakhshi et al., 1985; Tsuji-
moto et al., 1985).
In the World Health Organization (WHO) category of myeloid
malignancies with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) deregu-
lation of the proto-oncogene EVI1 (also termed MECOM or
PRDM3) at 3q26.2 is speculated to occur via juxtaposition of a
cryptic enhancer of the housekeeping gene RPN1 from 3q21
(Suzukawa et al., 1994). However, this hypothesis has not
been experimentally validated and the molecular basis of this
prognostically unfavorable subtype of malignancies remains
obscured. EVI1 expression and function is indispensable for
proper regulation of the hematopoietic stem cell compartment
and genomic integrity (Goyama et al., 2008; Kataoka et al.,
2011; Pinheiro et al., 2012). The gene was originally described
as a hotspot for proviral integration in retrovirally induced murine
myeloid leukemias (Morishita et al., 1988) and also represents
an important insertional mutagenesis site in humans following
gene therapy for X-linked granulomatous disease (Stein et al.,
2010).
We tested the hypothesis that rearrangements causing the
transcriptional activation of EVI1 involve the reallocation of an
enhancer element to the ectopic 3q26.2/EVI1 target site, which
may possibly coincide with a loss of enhancer activity at its
endogenous location. We applied an integrated functional
genomics and genome-engineering approach to identify a distal
enhancer of the GATA2 gene that, upon chromosomal 3q
rearrangements, ectopically activates EVI1 expression. Simulta-
neously, the removal of this enhancer from its natural genomic
context causes functional GATA2 haploinsufficiency, i.e.,
reduced GATA2 expression only from the remaining normal
allele.Cell 157, 369–381, April 10, 2014 ª2014 Elsevier Inc. 369
RESULTS
An 18 kb Noncoding Region near RPN1 Commonly
Translocates to EVI1 in inv(3)/t(3;3) Disease
We performed targeted next generation sequencing (NGS) of
the long arm of chromosome 3 (3q-seq) using genomic DNA
isolated from 41 samples with confirmed EVI1 overexpression
(EVI1+) and harboring an inv(3)(q21q26.2) or a t(3;3)(q21;q26.2)
(inv(3)/t(3;3)). The samples included 38 primary bone marrow
samples from patients, i.e., AML (n = 33), CML-BC (n = 2), and
MDS cases (n = 3), as well as three cell lines (MUTZ-3,
MOLM-1, and UCSD-AML1) (Table S1 available online). Chro-
mosomal breakpoint positions and novel junction sequences
of each case were determined by a breakpoint detection
algorithm in conjunction with a de novo assembly tool and
validated by Sanger sequencing. Characteristic breakpoint
patterns emerged at both 3q21 and 3q26.2 breakpoint cluster
regions (Figure 1A). At the 3q26.2 site, samples harboring an
inv(3) exclusively exhibited breakpoints in the last intron or
downstream of EVI1. Breakpoints in t(3;3) cases distinctly map-
ped upstream of EVI1, i.e., within the gene locus of the longer
splice variant that includes MDS1-EVI1 (Figure 1A). At the 3q21
site, breakpoints occurred in a 130 kb region between GATA2
(centromeric) and RPN1 (telomeric). A minimal 18 kb noncoding
region 30 ofRPN1 demarcated by chromosomal breakpoints was
identified as a commonly translocated segment (hereafter
referred to as CTS) (Figure 1B), which in all cases underwent
transpositioning to the vicinity of EVI1 due to the inv(3)/t(3;3)
rearrangement. This converging tell-tale pattern of 3q21
breakpoints toward an unaffected 18 kb genomic segment led
us to predict the presence of potent regulatory elements within
the CTS, essential for aberrant activation of EVI1 upon
rearrangement.
TheEVI1Promoter and the 18 kbCTSPhysically Interact
A hallmark of distal enhancer elements is their engagement in
chromatin loops physically contacting with promoters to induce
transcription factor assembly and polymerase II recruitment
(Deng et al., 2012; Sanyal et al., 2012; Thurman et al., 2012; Tol-
huis et al., 2002). To test whether the CTS harbored elements
physically interacting with the EVI1 promoter, we performed
high-resolution chromosome conformation capture sequencing
(4C-seq) experiments (van de Werken et al., 2012). Using view-
points placed on the EVI1 promoter in viable inv(3)/t(3;3) AML
samples and cell lines, we identified a genomic segment of
approximately 9 kb size within the 18 kb CTS contacting with
the EVI1 promoter (Figures 1C and 1D). Other contact regions
located centromeric of this 9 kb contact hotspot in closer dis-
tance to the EVI1 promoter after the rearrangement, as observed
in individual samples with different breakpoint positions, were
considered less likely enhancer candidates. These regions
were nonoverlapping across different samples and thus repre-
sented less specific contacts, which became more evident after
integrative analysis of all 3q-rearranged AML samples (Fig-
ure 1D). Reciprocal 4C-seq experiments with the putative 9kb
region as viewpoint showed that the interaction with the EVI1
promoter area was also evident (Figure S1). As expected, no
substantial chromatin interactions with the distant EVI1 promoter370 Cell 157, 369–381, April 10, 2014 ª2014 Elsevier Inc.could be detected in 4C-seq experiments with non-3q-rear-
ranged control (U937), suggesting an inv(3)/t(3;3) disease-
specific feature (Figures 1C and S1).
A p300-Bound Genomic Element in the 18kb CTS Is
Essential for EVI1 Activation
In order to identify a more defined, targetable key enhancer
element within the 9 kb EVI1-promoter-contact part of the
18 kb CTS, we integrated data from 4C-seq with ChIP-seq
data obtained from inv(3) cell lines MOLM-1 and MUTZ-3
(Figures 2A and S2). Prominent deposition of H3K27ac,
H3K4me3, and H3K4me1 was observed within the 18 kb CTS,
as well as strong binding of p300 to two regions of approximately
1 kb size in MOLM-1 (Figure 2A). In MUTZ-3 cells only one
p300-interacting region was identified (Figure S2), which is
the p300 peak located in the 9 kb EVI1-promoter-contact
part of the CTS as determined by 4C-seq. Comparison with
ENCODE ChIP-seq data of various nonmyeloid cell lines and
transcription factor motif analysis pointed to a 1 kb myeloid
hematopoiesis-specific enhancer (Figures 2A and S2). This
p300-binding site was chosen as the most likely candidate
enhancer element responsible for ectopic EVI1 activation
after the rearrangement event. We placed the two candidate
enhancers (first and second p300 site) into an EVI1-promoter
luciferase reporter construct to study their potential enhancer
activity (Figure 2B). A strong induction of reporter gene activity
could be observed specifically in inv(3) myeloid cell lines
MUTZ-3 and MOLM-1 using the first candidate enhancer
element, whereas the second candidate enhancer element
(second p300 site) located within the 18 kb CTS, but outside of
the 9 kb EVI1-promoter-contact region, showed no enhancer ac-
tivity. No activity was found for two distinct CTCF-
interacting CpG islands colocalizing to the CTS. Moreover,
EVI1-promoter reporter assays demonstrated no substantial
enhancing effect of the candidate 1 kb enhancer in nonmyeloid
HEK293T or Jurkat cells, pointing to a myeloid-specific tran-
scription factor repertoire required for successful enhancer-
EVI1-promoter engagement.
Genome Editing of the Translocated p300-Interaction
Domain Leads to EVI1 Silencing and Growth Inhibition of
inv(3) AML Cells
We next undertook a TALE nuclease genome-editing approach
to target the ectopic EVI1 enhancer locus in the MUTZ-3 cell
line and to examine whether EVI1 transcriptional activity in
inv(3) AML cells is dependent on the presence of the rearranged
candidate enhancer (first p300 peak). TALE nucleases were
assembled as previously published (Sanjana et al., 2012), and
targeting of the minimal ectopic enhancer site was performed
in a 2 3 2 design (details in Experimental Procedures), directing
TALEN heterodimers to enhancer-flanking recognition se-
quences to induce a segmental deletion by double-strand
breaks (DSB) (Figure 3A). Mutation-specific primers allowed
for allelic detection of the deletion event (Figure 3B) and for
screening of clones using an informative SNV in the candidate
enhancer locus of MUTZ-3 (Figures 3B, S3A, and S3B). Overall
targeting efficiency was 1%with 4/384 single-cell derived clones
harboring a monoallelic enhancer deletion on the inv(3) allele
Figure 1. Chromosomal Breakpoint Architecture in inv(3)/t(3;3) AML and Local 3q21 Chromatin Interaction Profiles of the EVI1 Promoter
(A) Mapping of chromosomal breakpoints (arrowheads) by targeted 3q-capture NGS revealing two characteristic breakpoint patterns at 3q21 (left) and 3q26.2
(right).
(B) The 3q21 breakpoint cluster and rearranged chromosomal segments of individual AML samples are represented by red arrowed lines, plotted by distance to
the RPN1 gene locus. A breakpoint-free commonly translocated segment (CTS) of 18 kb size is indicated (blue box).
(C) The local chromatin interaction profile of the EVI1 promoter region with the 3q21 breakpoint cluster was determined by 4C-seq in representative inv(3)/t(3;3)
cases. The 4C signal is measured by calculation of a sliding window average (runningmean) of the normalized read counts (window size is 21 fragment ends). The
vertical axis is scaled to themaximum 4C signal per sample. An overlapping contact hotspot of 9 kb size within the CTS in 3q-rearranged cases is highlighted as a
blue box. The non-3q-rearranged cell line U937 was used as control.
(D) Integrated local contact profile analysis of all 3q-rearranged samples. In the top panel (main trend), the contact intensity (black line) is calculated by using a
running median analysis of normalized read counts with a 5 kb sliding window. The 20th and 80th percentile are visualized as a gray trend graph. In the bottom
panel, contact intensities are computed using linearly increasing sliding windows (scaled 2-50 kb) and are displayed as a color-coded heatmap of positive 4C
signals (maximum of interaction set to 1). Local color changes are log-scaled to indicate changes of statistical enrichment of captured sequences, corresponding
to the enhancer-promoter interaction.
See also Figure S1 and Table S1.(Figure S3C). Enhancer-targeting effectively attenuated EVI1
mRNA expression in deletion clones as compared with nontar-
geted MUTZ-3 control clones taken along in the same targeting
process (Figure 3C). RPN1 and GATA2 mRNA expression re-mained unchanged in inv(3)-targeted clones. Notably, all four
TALEN-modified MUTZ-3 clones showed severely impaired
colony-forming and replating capacity compared to nontargeted
clones (Figure 3D).Cell 157, 369–381, April 10, 2014 ª2014 Elsevier Inc. 371
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Figure 2. Combined ChIP-Seq and 4C-Seq Discloses Putative Enhancer Elements in the EVI1 Promoter-Interacting Rearrangement Site
(A) Binding of p300 (red track) in the 9 kb EVI1-interaction domain of the 18 kb CTS (divided blue box) is detectable in inv(3)/t(3;3) samples. ChIP-seq profiles of
p300 and active chromatin marks H3K27ac, H3K4me3, and H3K4me1 of the inv(3) cell line MOLM-1 indicate an inv(3) cell-type-specific enrichment in the CTS,
not found in non-3q-rearranged cell lines of various tissue origin (ENCODE: GM12878, H1-hESC, HeLa-S3, HepG2, HSMM, HUVEC, K562, NHEK, NHLF). Based
on ChIP-seq enhancer profiles and CpG island prediction, two candidate enhancer regions were selected both inside (denoted first p300 and CpG1; blue and
green bars) and outside (denoted second p300 and CpG2; blue and green bars) of the 9 kb EVI1-interaction domain of the CTS, respectively, for subsequent
reporter assays.
(B) Selected candidate elements were cloned into EVI1-promoter luciferase reporter constructs and transfected into MUTZ-3, MOLM-1, HEK293T, or Jurkat
cells. After 48 hr, cells were harvested and luciferase assayswere performed. Relative luciferase induction is plotted as fold change compared to enhancer-empty
control vector (mean ± SEM).
See also Figure S2.Deletion of the Ectopic EVI1 Enhancer Releases the
Maturation Block of inv(3) AML Cells
Genome editing in MUTZ-3 AML cells using TALENs did not
allow for high yields of viable cells lacking the enhancer because
of the low targeting efficiency of this genetic tool in the inv(3)
cell line model followed by a long and indirect selection process
of growth-impaired deletion clones. To better characterize the
cellular phenotype and fate after enhancer deletion, we designed
an alternative targeting approach using the CRISPR/Cas9
genome-editing system with a site-specific homology-directed
repair (HDR) donor for direct labeling and tracking of success-
fully targeted cells (Figures 4A and 4B). In brief, enhancer
deletions were induced by two short guide-RNAs (gRNA) direct-
ing hSpCas9 to two enhancer-flanking recognition sequences372 Cell 157, 369–381, April 10, 2014 ª2014 Elsevier Inc.for DSB formation and HDR of the induced segmental deletion
by means of a cotransfected HDR donor construct containing
a conditional (loxP-) GFP selection cassette directed against
the enhancer (details in Experimental Procedures). The genomic
CMV-GFP insertion was subsequently removed by using exoge-
nous cell-permeant Cre recombinase (TAT-Cre). This approach
enabled us to isolate sufficient cell numbers for phenotypic
characterization. Deletion events and transcriptional changes
were confirmed by Sanger sequencing and qPCR (Figures 4C
and S3D). Compared to untargeted control MUTZ-3 cells,
targeted cells exhibited a markedly reduced proliferative rate
as assessed by viable cell count using trypan blue staining
(Figure 4D). Cell cycle analysis showed depletion of S phase
and G2/M phase combined with higher rates of cell death
(sub-G0/G1 peak) and a stationary G0/G1 cycle arrest (Fig-
ure 4E). Remarkably, flow cytometric immunophenotyping of en-
gineered cells using a panel of informativemyeloid differentiation
markers (see Extended Experimental Procedures for detailed
list) according to published guidelines (van Dongen et al.,
2012) revealed a substantial skew toward a more mature, mye-
lomonocytic stage as per cMPO and CD14 expression levels
3 weeks after genome editing (Figure 4F). Cytologic evaluation
of enhancer-targeted MUTZ-3 cells in week 3 after genomic
modification confirmed morphologic changes from the predom-
inantly immature, myelomonocytic appearance of untargeted
cells toward a more differentiated, monocyte/macrophage-like
shape (Figure 4G). This also translated into a higher apoptotic
rate of CRISPR-targeted MUTZ-3 cells 3 weeks after enhancer
deletion (Figure 4H).
Off-target mutagenesis at alternative in silico predicted sites
was excluded by Sanger sequencing (Figure S3E). The pheno-
type observed upon enhancer deletion by genome-editing tools
was highly comparable to whatwas foundwith small hairpin RNA
(shRNA)-mediated EVI1 knockdown in the MUTZ-3 cell line
(Figures S4A–S4H), emphasizing that MUTZ-3 cells are addicted
to EVI1 and blocked in their differentiation. We did not observe
outgrowth of biallelic enhancer deletion or monoallelic mutants
of the nonrearranged chromosome 3 allele, hinting toward
negative selection of these mutants upon disruption of the
enhancer at its natural genomic location.
The Candidate Enhancer Translocated to EVI1 Is an
Original Upstream Enhancer of GATA2
The most likely candidate for off-target mutagenesis at the
original enhancer-associated domain on the normal chro-
mosome 3 allele appeared to be RPN1 due to its immediate
proximity to the candidate enhancer. Concordantly, RPN1 has
therefore generally been the assumed origin of ectopic EVI1
regulatory elements, since it is located in the proximity of the
chromosome 3 breakpoint cluster (Suzukawa et al., 1994;
Wieser et al., 2003). Thus, disturbance of the housekeeping
function of RPN1 on the remaining normal allele would most
likely be deleterious. However, analysis of our 4C-seq profiling
data instead revealed substantial interactions between the
candidate enhancer and the promoter of GATA2 rather than
with the promoter of RPN1 (Figures 5A, 5B, and S5A). GATA2
is a crucial hematopoietic stem cell regulator, located on the
contralateral side of the 3q21 breakpoint cluster. This
suggests that the candidate enhancer is an original upstream
regulatory element for GATA2, rather than RPN1. Hi-C data
confirm that the candidate enhancer is together with the
GATA2 locus in a topological domain, physically segregated
from the more proximal RPN1 promoter (Dixon et al., 2012)
(Figure S5B).
Consequently, we first aimed to examine the effect of loss of
the candidate enhancer in a human cell line without 3q rear-
rangements and the functional impact on either RPN1 or
GATA2 expression. We generated custom CRISPR/Cas9
nucleases against the candidate enhancer locus in the GATA2-
expressing erythroleukemia cell line K562 (Figure 6A). We effec-
tively deleted the candidate enhancer in K562 cells and
observed profoundly reduced levels (10.8-fold) of GATA2mRNA in targeted K562 pools (Figure 6B), whereas RPN1
expression levels remained unchanged. Luciferase GATA2-
promoter reporter studies confirmed strong GATA2-specific
enhancer activity of the candidate locus in a myeloid context
(Figure 6C). Thus, the candidate ectopic enhancer, which upon
translocation is repositioned to the EVI1 locus, is a strong
enhancer of GATA2 in its original chromosomal context.
Rearrangement of the GATA2 Enhancer to EVI1 Causes
Functional Haploinsufficiency of GATA2
To study the effects of the enhancer translocation on GATA2
expression in inv(3)/t(3;3) AML samples, we analyzed allele fre-
quencies of informative SNPs in the GATA2 locus by combining
3q-seq and RNA-seq data. This integrative analysis revealed a
monoallelic expression pattern of GATA2 in all 36 inv(3)/t(3;3)
cases studied (Figures 6D and S6). Non-3q-rearranged AML
patient samples and cell lines, as well as variant 3q-rearranged
AML cases (e.g., inv(3)(q21q25); t(3;7)(q26;p15)) displayed a
normal, biallelic GATA2 expression pattern (data not shown).
To ascertain monoallelic GATA2 expression originating from
the normal chromosome 3 allele, we performed an allele-specific
chromosome conformation capture sequencing approach (see
Experimental Procedures for details), in which captured informa-
tive SNPs of the GATA2 locus can only be amplified by allele-
specific primers on the nonrearranged, linear chromosome 3
template. Results were validated by long-range, breakpoint-
spanning PCR and Sanger sequencing. By integration of results
from these NGS platforms (3q-seq, RNA-seq, and allele-specific
4C; Figure 6D), we found monoallelic GATA2 expression as a
consequence of GATA2 inactivation on the rearranged allele in
cases harboring inv(3) or t(3;3). Notably, GATA2 expression
levels in primary inv(3)/t(3;3) AML cases and cell lines (n = 78)
were found to be significantly reduced as compared to controls
(213 AML patients) (Figure 6E). Thus, our data indicate that the
inversion/translocation event in inv(3)/t(3;3) malignancies reorga-
nizes an originally upstream regulatory element of the GATA2
domain, causing reduced andmonoallelic expression ofGATA2.
The 18 kb CTS and p300-Interaction Domain Are Part of
a Translocation-Derived Superenhancer
We have shown that targeting of the candidate enhancer site in
inv(3) AML cells by genome-editing techniques is feasible, based
on the premises that the enhancer element interacts with the
EVI1 promoter, binds the transcriptional coactivator p300, and
is embedded in a region of open, potentially regulatory chro-
matin, and thereby also accessible for endonucleases. However,
ChIP-seq data obtained from the inv(3) cell line MOLM-1 mani-
fested a large segment of H3K27ac deposition that extends
beyond the entire 18 kb CTS and p300-interaction domain,
covering a region of approximately 40 kb (Figures 2A and 7A).
These exceptionally large enhancer domains with high levels of
H3K27ac and the chromatin regulator BRD4 have recently
been characterized as superenhancers (Love´n et al., 2013;
Whyte et al., 2013). Using the bioinformatic analysis tool ROSE
(Love´n et al., 2013), the 40 kb H3K27ac-deposition region was
identified as a superenhancer, ranking second among 291
superenhancers in the MOLM-1 genome (Figures 7A and 7B).
RNA-seq analysis revealed the presence of intense read-throughCell 157, 369–381, April 10, 2014 ª2014 Elsevier Inc. 373
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enhancer RNAs (eRNAs) spanning the entire superenhancer area
including the 18 kb CTS in MOLM-1 (Figure 7A). Of note, read-
through transcription commenced precisely at the breakpoint
positions, representing the fusion point of 3q21 with 3q26/EVI1
segments. RNA-seq carried out in all available inv(3)/t(3;3) leuke-
mia samples disclosed identical patterns of large read-through
areas of eRNAs (Figure 7A). Consistently, BRD4-occupancy
was found at the superenhancer site in 3q-rearranged samples,
particularly in the p300-interaction domain (Figure S7A). Non-3q-
rearranged samples entirely lacked traces of transcriptional
read-through (Figure 7A) and exhibited no H3K27ac deposition,
or, if any at all, only in a confined 3–4 kb region immediately
downstream of the RPN1 gene, as shown by comparison with
ENCODE ChIP-seq data of various non-3q-rearranged cell lines
(Figures 2A and S2). Furthermore, combining 3q-capture DNA-
seq with ChIP-seq data of MOLM-1 showed the presence of
informative heterozygous SNPs in the putative 3q21 superen-
hancer locus on genomic DNA level, whereas the chromatin after
H3K27ac pull-down revealed a skew in the allelic ratio of these
SNPs in the same locus (Figure 7C). These observations suggest
the presence of an active, rearranged superenhancer in inv(3)/
t(3;3) leukemia samples, as was previously observed for MYC-
rearrangements in multiple myeloma (Love´n et al., 2013).
BET Inhibition Leads to EVI1 Silencing and Growth
Arrest of inv(3)/t(3;3) AML Cells
Our genome-editing results underline that EVI1 is the key
oncogenic driver in inv(3)/t(3;3) AML and vulnerable to interfer-
ence with its ectopic enhancer. As reported previously, BET-
bromodomain inhibition of superenhancers represents a novel
therapeutic avenue to target genes particularly regulated by
superenhancers (Love´n et al., 2013; Whyte et al., 2013). The
observation that the p300-binding ectopic EVI1 enhancer is
embedded in a large 3q21 superenhancer complex (Figures 7A
and 7B) prompted us to investigate whether EVI1 transcription
in inv(3)/t(3;3) AMLs is sensitive to enhancer interference by
treatment with a BET-bromodomain inhibitor (JQ1). Exposure
of MUTZ-3 and MOLM-1 cells, as well as primary inv(3)/t(3;3)
AML samples to JQ1 profoundly inhibited proliferation with con-
centrations >50 nM (Figures 7D and S7C). EVI1-expressing K562
cells (no 3q rearrangement), however, were not responsive to
JQ1, as was previously shown (Zuber et al., 2011). EVI1 mRNA
levels inMUTZ-3 andMOLM-1 cells significantly decreased after
JQ1 treatment contrary to K562 cells, in which BRD4 density at
the enhancer locus is lower by comparison (Figures 7E, S7A,
S7D, and S7E). Furthermore, GATA2 mRNA levels did notFigure 3. TALEN-Targeted Candidate Enhancer-Deletion Clones Exhib
(A) Schematic representation of the targeting construct and target sites flanking th
the 9 kb EVI1-interaction domain of the CTS (blue box). Four TALENs were design
cleavage of the 16–18 bp intervening linker sequence (black). Arrows indicate pr
(B) Representative gel image demonstrating efficient induction of segmental delet
efficiency as per gel quantification 48 hr after transfection).
(C) EVI1,GATA2, and RPN1mRNA expression analysis by qPCR of genome-edite
Relative mRNA expression levels were calculated using theDDCt method, with ex
PBGD mRNA levels. Error bars denote standard deviation (SD).
(D) Comparison of colony formation of targeted and unmodified clones. Colon
methylcellulose.
See also Figure S3.change upon JQ1 treatment, substantiating the notion that the
ectopic superenhancer/core p300 element is indeed a fusion
result regulating EVI1 on the rearranged allele rather than
GATA2 on the remaining normal allele. BRD4 load as well as
read-through transcription at the ectopic EVI1 superenhancer
site were substantially decreased after JQ1 treatment (Figures
7F and S7B), whereas displacement of BRD4 in typical enhancer
regions was less profound, as has previously been reported
(Whyte et al., 2013). Similar to the observed effects upon
enhancer excision, we observed a profound S phase reduction
along with a G0/G1 cell-cycle arrest, higher rates of maturation,
and apoptotic events upon BRD4-inhibition (Figures 7G, S7F,
S7G, and S7H). Reintroduction of EVI1 by nucleofection of
MUTZ-3 cells prior to JQ1 treatment, allowing for transient
EVI1 expression, partly rescued MUTZ-3 from JQ1 cytotoxicity,
arguing for relative selectivity of JQ1 for the EVI1 superenhancer
as opposed to globally inhibiting other putative oncogenic
drivers (Figure 7H).
DISCUSSION
In summary, inv(3)/t(3;3) chromosomal rearrangements cause
dysregulation of two specific AML predisposition genes by
aberrant activity of a single enhancer element in its ectopic
chromatin environment: (1) Overexpression of EVI1 is caused
by inappropriate transcriptional control of the ectopic GATA2
regulatory element, while (2) GATA2 transcriptional impairment
results from the removal of that same enhancer from its
genomic origin. These dual events mediated by a single
enhancer rearrangement, without formation of an oncogenic
fusion product, highlight the vulnerability of genome organiza-
tion into long-range regulatory interaction domains in case of
a chromosomal break. The enhancer we identified appears to
originally control transcription of the 110 kb distant GATA2
gene at 3q21, and not the nearby gene RPN1. Our finding is
in accordance with reports demonstrating a highly homo-
logous 77 kb enhancer element to constitute a component
of the murine Gata2 master regulatory complex (Grass et al.,
2006) and that this element is indeed leukemogenic via EVI1
activation in transgenic mice harboring the human 3q21q26-
rearranged allele (Yamazaki et al., 2014). In case of an inv(3)/
t(3;3), the rearranged enhancer engaged in chromatin loops
with the EVI1 promoter, in certain samples over a distance of
more than 200 kb. Our data emphasize that the function of an
enhancer is not only determined by its location, but in particular
by its ability to physically bind to an appropriate promoter,it Severely Reduced EVI1 mRNA Levels and Replating Capacity
e previously identified p300-binding candidate enhancer (red ChIP-seq track) in
ed for pairwise heterodimeric binding to indicated target sequences (blue) and
imer locations for PCR analysis.
ions only in the presence of two TALEN pairs (MUTZ-3 cell line; 2.4% targeting
d MUTZ-3 mutants after TALEN-targeting of the candidate enhancer on inv(3).
pression levels of the cell line SKOV3 serving as calibrator and with reference to
y numbers and sizes were determined after 2 and 6 weeks after replating in
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Figure 4. Genomic Enhancer Excision Induces Proliferative and Differentiation Changes in inv(3) AML Cells
(A) Schematic representation of the CRISPR/Cas9 licensing gRNAs with protospacer-adjacent motifs (PAM) highlighted in blue, the target locus, and the donor
construct for site-directed homology repair using a conditional, floxed pCMV-GFP selection cassette.
(B) Timeline of genomic targeting of MUTZ-3 AML cells.
(C) Detection of deletion events by genomic PCR of sequential cell fractions. Representative Sanger sequencing tracks of purified PCR amplicons of the GFP-
insertion band (2.3 kb) and a remaining lower-running, normal allele band of 1.5 kb size are shown (from GFP+ fraction of day 14), revealing a monoallelic deletion
indicated by a loss of heterozygosity of the SNV present in the targeted enhancer locus (red asterisk).
(D) Proliferation of untargeted control and targeted cells was measured by counting of viable cells using trypan blue.
(E) Cell-cycle analysis of control and genome-edited MUTZ-3 cells harvested after 3 weeks of selection.
(legend continued on next page)
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Figure 5. The Nonrearranged Candidate Enhancer Is Part of the GATA2 Enhancer Complex
(A) Representative 4C data (n = 7 biological replicates) showing the local contact profile using a window of 21 with the first p300 peak site as viewpoint (red
dashed line).
(B) Integrative 4C analysis using a viewpoint from theGATA2 promoter region (n = 7 biological replicates). In the top panel (main trend), the contact intensity (black
line) is calculated by using a running median analysis of normalized read counts with a 5 kb sliding window. The 20th and 80th percentile are visualized as a gray
trend graph. In the bottom panel, contact intensities are computed using linearly increasing sliding windows (scaled 2–50 kb) and displayed as a color-coded
heatmap of positive 4C signal (maximum of interaction set to 1). Local color changes are log-scaled to indicate changes of statistical enrichment of captured
sequences, corresponding to the enhancer-promoter interaction (red dashed lines).
See also Figure S5.which can even occur in a different chromosome topology. Our
findings show that not RPN1, as reported in the nomenclature of
the WHO2008 classification (inv(3)/t(3;3)/RPN1-EVI1), but rather
the GATA2 locus is the source of the ectopic enhancer acti-
vating EVI1 in this type of leukemia.
Besides aberrant EVI1 activation, rewiring of parts of the
GATA2 and EVI1 domains led to a reduction of GATA2 expres-
sion levels. EVI1 activation in this subtype of AML argues for a
primitive HSC defect (de Pater et al., 2013; Goyama et al.,
2008; Kataoka et al., 2011; Ling et al., 2004; Orlic et al.,
1995; Spinner et al., 2013; Tsai and Orkin, 1997). Since
GATA2 is a critical hematopoietic stemness factor, primitive he-
matopoietic precursors will be particularly susceptible to distur-
bances of GATA2 homeostasis. Thus, GATA2 deficiency may
provide the right spatiotemporal context for EVI1 oncogene
activation, i.e., in the right cell at the right stage of differentia-
tion for subsequent malignant transformation. Functional hap-
loinsufficiency arising from inactivating mutations in GATA2
DNA-binding domains or in GATA2 regulatory sequences rep-
resents a well-established underlying cause of MDS/AML and
Emberger/MonoMAC syndromes (Hahn et al., 2011; Hsu
et al., 2013; Hsu et al., 2011; Ostergaard et al., 2011; Rodrigues(F) Immunophenotyping of control and enhancer-targeted MUTZ-3 cells. The lef
show the myelomonocytic maturation. The right panel shows the distribution o
CD14) = blast cell; intermediate (CD34/CD14-) = promonocyte; mature (CD34
(G) Representative images of May-Gru¨nwald-Giemsa staining of control and enh
(H) Assessment of apoptosis in control (top) and enhancer-targetedMUTZ-3 cells
with percentages for each gate are shown.
See also Figures S3 and S4.et al., 2005), of which the latter are characterized by monocy-
topenia, immune deficiency, and predisposition to myeloid leu-
kemia with frequent monosomy 7. AML with inv(3)/t(3;3) most
commonly associates with monosomy 7 and trilineage
dysplasia, and, as demonstrated here, it is accompanied by
impaired GATA2 expression as well. It will be of particular inter-
est to investigate whether in Emberger and MonoMAC patients
3q26 defects and consequently aberrant EVI1 expression are
also drivers of disease progression toward AML/MDS. Of
note, the enhancer-containing 3q21 locus is rarely, but consis-
tently involved in other chromosomal rearrangements with
PRDM homologs of the EVI1 gene (e.g., BLIMP1/PRDM1 or
MEL1/PRDM16) and their aberrant activation (Lugthart et al.,
2010). Both disease categories (inv(3)/t(3;3) and other t(3q21)
AMLs) resemble each other by their high white blood cell and
exceptionally high platelet counts at diagnosis. Further studies
using in vivo models are warranted to investigate how the com-
bined effects of GATA2 haploinsufficiency and overexpression
of EVI1 or its homologs cooperate in malignant transformation
of primitive hematopoietic progenitors.
The ectopic EVI1 enhancer was embedded in a genomic
region exhibiting large deposition of active chromatin markst panel includes two dot plots per sample (CD34/CD14 and CD34/cMPO) that
f the various maturation stages, simplified in three stages: immature (CD34+/
/CD14+) = monocyte.
ancer-targeted MUTZ-3 cells (1003 magnification).
(bottom). Representative flow cytometry plots for Annexin V and 7-AAD staining
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A B
C D E
Figure 6. Loss of the GATA2 Candidate Enhancer Leads to Functional Haploinsufficiency of the Affected GATA2 Allele
(A) Schematic of the CRISPR nuclease design for candidate enhancer targeting. Arrows indicate primer locations for PCR analysis. For each construct, the
protospacer sequence and the Cas9-specific proximal-adjacent motif (PAM; magenta highlight) are indicated.
(B) Upon transfection of the candidate enhancer-flanking CRISPR constructs, K562 cells were analyzed by deletion-specific PCR (gel image). Unsorted cells
represented pools of CRISPR-targeted and nontargeted cells. GFP-sorted and isolated deletion clones harbored predominantly biallelic deletion mutants.
GATA2 and RPN1 mRNA expression was analyzed by qPCR (right). Error bars denote SD.
(C) The p300-binding core enhancer region and an adjacent control region (second p300 peak region) were cloned into a GATA2-promoter luciferase reporter
construct, and luciferase activity was measured 48 hr after transfection of indicated cell lines. GATA2+ MUTZ-3 cells, as well as GATA2- nonmyeloid HEK293T
and Jurkat cells were assayed. Relative luciferase induction is plotted as fold change compared to enhancer-empty control vector (mean ± SEM).
(D) Integrated analysis of 3q-DNA-seq, RNA-seq, and allele-specific 4C-seq data of a representative inv(3) AML case reveals monoallelic expression of GATA2
mRNA from the intact chromosome 3q21 allele.
(E) GATA2 expression level analysis by qPCR in inv(3)/t(3;3) AML (n = 78) and unselected, non-3q-rearranged AMLs (n = 213; Mann-Whitney-U test, p = 0.002).
See also Figure S6.and presence of read-through transcripts. This class of DNA
elements has recently been recognized as so-called superen-
hancers (Whyte et al., 2013), which represent large open chro-
matin regions of >10 kb in size with key regulatory function for
cellular identity and oncogene regulation in cancer. The obser-
vation that the GATA2 enhancer region upon translocation had
acquired characteristics of a superenhancer, dominantly
ranking in the MOLM-1 genome, provided the rationale for378 Cell 157, 369–381, April 10, 2014 ª2014 Elsevier Inc.treatment with bromodomain/BET inhibitors (Love´n et al.,
2013). The presence of a 3q21 superenhancer might also
explain why JQ1 is effective in inv(3)/t(3;3) cell lines as
opposed to various non 3q-rearranged AML cell lines with
EVI1 overexpression (Zuber et al., 2011). The effects seen after
JQ1 treatment recapitulated the observations obtained by
genome-editing experiments involving the translocated p300-
interaction domain. Remodeling of the cancer genome by
A B
C D
E F G H
superenhancer
superenhancer
superenhancer
superenhancer
Figure 7. The Ectopic Enhancer Is Part of a 3q21 Superenhancer
(A) H3K27ac ChIP-seq (orange track) of theMOLM-1 cell line and RNA-seq (black tracks) of representative inv(3)/t(3;3) samples and non-3q-rearranged cell lines.
Red arrowheads denote chromosomal breakpoint positions per sample. The superenhancer region defined by the H3K27ac enrichment score is indicated as a
red bar.
(B) Ranking of superenhancers identified in the MOLM-1 genome as per H3K27ac enrichment.
(C) Allelic imbalance of the 3q21 superenhancer region is determined by comparison of allelic ratios obtained from 3q-seq and H3K27ac ChIP-seq using
informative, heterozygous SNPs (n = 6) present in the superenhancer domain. Allelic imbalances for SNPs are tested using a c2 goodness-of-fit test to identify
regions exhibiting ChIP-seq allelic ratios significantly different from the genomic allelic ratios (H0 = allelic ratios identical between ChIP-seq and 3q-DNA-seq
experiments).
(D) JQ1 treatment is effective in inv(3) AML cells (MUTZ-3) versus non-3q-rearranged cells (K562). JQ1 sensitivity wasmeasured bymitochondrial dehydrogenase
(MTT assay) after 6, 24, 48, and 72 hr of exposure with JQ1 (5, 50, 500, or 1,000 nM) or vehicle control (DMSO, 0.05%). Error bars represent the SD of triplicate
experiments.
(E) Analysis of EVI1 and GATA2 mRNA expression levels in MUTZ-3 and K562 by qPCR at different time points following JQ1 exposure (1,000 nM). Error bars
denote SD.
(F) ChIP-seq-binding profiles for BRD4 (blue) and H3K27ac (orange) at the 3q21 superenhancer locus (left) or at theWDR74 upstream enhancer after treatment of
MOLM-1 cells with JQ1 (1,000 nM) or DMSO (0.05%) for 6 hr.
(G) Cell cycle analysis of MUTZ-3 cells after treatment with DMSO (0.05%; top) or JQ1 (1,000 nM; bottom) for 24 hr.
(H) Transient EVI1 rescue counteracts JQ1 antiproliferative effect. Cells were nucleofected either without DNA (mock), or with an empty GFP-expressing vector
(EV) or a GFP-EVI1-expressing construct (EVI1), GFP-sorted after 24 hr, and subsequently exposed to JQ1 (1,000 nM) for following viability measurements at
indicated time points. Error bars represent the SD of triplicate experiments.
See also Figure S7.using in vivo nuclease as applied in this study helped to exper-
imentally validate EVI1 as an oncogenic driver lesion and war-
ranted further pharmacologic experiments interfering withenhancer activity. These experiments emphasized that target-
ing EVI1 transcriptional regulation using drugs directed against
enhancer complexes could have therapeutic potential for thisCell 157, 369–381, April 10, 2014 ª2014 Elsevier Inc. 379
highly refractory subgroup of AML and diseases driven by
similar mechanisms.
EXPERIMENTAL PROCEDURES
Subjects
Patient recruitment and sample processing were performed according to
protocols from the German-Austrian Acute Myeloid Leukemia Study Group
(AMLSG trials 06-04, 07-04, HD93A, HD98A/B) and the Dutch-Belgian
Hematology/Oncology Cooperative Group (HOVON trials 04/A, 29, 42, 43,
81, 92). All studies were approved through institutional human ethics review
board, and all patients provided written informed consent in accordance
with the Declaration of Helsinki.
Generation of TALEN Constructs
Construction of TALE DNA-binding domains directed to selected genomic loci
was performed as described previously (Sanjana et al., 2012). Genomic target
coordinates were selected and filtered for off-target sites using the TAL
Effector Nucleotide Targeter 2.0 tool (https://tale-nt.cac.cornell.edu/node/
add/talen). Spacer length was defined within a range of 16–20 bp, and repeat
array length was set to 20 bp. The NN repeat variable domain targeting base G
was chosen in the assembly. In brief, hexamer modules were assembled from
a PCR-amplified monomer library using a hierarchical digestion-ligation reac-
tion and subsequently cloned into a full-length TALEN construct. Plasmids
were verified by Sanger sequencing and tested for functionality upon transfec-
tion in HEK293T cells. To induce a genomic deletion, two TALEN pairs were
transfected owing to dimerization requirement of the FokI nuclease for dou-
ble-strand break formation. Repair of chromatin cleavage at the left/upstream
and right/downstream boundaries of the target locus relies on nonhomologous
end joining (NHEJ) in the absence of a repair donor and results in the deletion of
a TALEN-targeted DNA segment.
Generation of CRISPR Constructs
In this study, the RNA-guided endonuclease genome-editing system was
employed in experiments involving the cell lines MUTZ-3 and K562 owing to
its cell-line-specific superior targeting efficiency compared with TALENs
genome-editing approaches (Mali et al., 2013). Publicly available plasmids
expressing the CRISPR (clustered regularly interspaced short palindromic
repeats)/Cas9 system were used for cloning of targeting constructs following
recently published protocols (Cong et al., 2013; Mali et al., 2013). In brief,
custom target-specific oligonucleotides were cloned into a chimeric guide
RNA array of an hSpCas9-expressing targeting vector. Oligonucleotides for
site-specific chromatin cleavage of genomic target regions were designed
following described guidelines and selected for uniqueness using a
bioinformatic filtering tool (http://www.genome-engineering.org/crispr/). To
induce segmental deletions of candidate regulatory DNA regions, two
CRISPR plasmids were transfected into cells. Each construct was directed
to flanking target site positions of the intervening DNA segment for induction
of NHEJ-mediated repair upon DSB formation. Cells were screened for
deletion events 48 or 72 hr later by mutation-specific PCR analogous to
TALENs experiments.
Clone Screening and Sequencing
Upon expansion of TALEN- or CRISPR-targeted clones, genomic DNA
was isolated with the QuickExtract DNA Extraction Solution (Epicenter)
and screened for deletion events by mutation-specific PCR using primers
spanning the breakpoint junction. A shift in amplicon size visualized by appear-
ance of a lower running band on gel electrophoresis indicated successful
targeting, and candidate clones were subsequently checked for mono-
clonality. The native amplicon and novel fusion fragment of candidate clones
were separately purified, and sequences of informative, heterozygous SNVs
in the target region were determined by Sanger sequencing. Monoallelic
targeting was confirmed by loss of heterozygosity at the SNV-specific nucle-
otide site. Monoclonal biallelic deletion mutants were detected by loss of the
native amplicon and presence of a single, novel fusion fragment represented
by the lower running band.380 Cell 157, 369–381, April 10, 2014 ª2014 Elsevier Inc.ACCESSION NUMBERS
ChIP-seq and RNA-seq data derived from cell lines are available in the
ArrayExpress database (www.ebi.ac.uk/arrayexpress) under accession
numbers E-MTAB-2224 and E-MTAB-2225.
4C-seq data and 3q-seq data derived from cell lines have been deposited at
the European Nucleotide Archive (ENA, http://www.ebi.ac.uk/ena/), which is
hosted by the EBI, under accession numbers PRJEB5236 and PRJEB5233.
3q-seq data and RNA-seq data derived from patient specimens have been
deposited at the European Genome-phenome Archive (EGA, https://www.
ebi.ac.uk/ega/), which is hosted by the EBI, under accession number
EGAS00001000669.
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